Abstract
Friedreich ataxia (FRDA) is the most common autosomal recessive ataxia worldwide. This review highlights the main clinical features, pathophysiological mechanisms, and therapeutic approaches for FRDA patients. The disease is characterized by a combination of neurological involvement (ataxia and neuropathy), cardiomyopathy, skeletal abnormalities, and glucose metabolism disturbances. FRDA is caused by expanded guanine-adenine-adenine (GAA) triplet repeats in the first intron of the frataxin gene (FXN), resulting in reduction of messenger RNA and protein levels of frataxin in different tissues. The molecular and metabolic disturbances, including iron accumulation, lead to pathological changes characterized by spinal cord and dorsal root ganglia atrophy, dentate nucleus atrophy without global cerebellar volume reduction, and hypertrophic cardiomyopathy. DNA analysis is the hallmark for the diagnosis of FRDA. There is no specific treatment to stop the disease progression in FRDA patients. However, a number of drugs are under investigation. Therapeutic approaches intend to improve mitochondrial functioning and to increase FXN expression.
Similar content being viewed by others
References
Delatycki MB, Corben LA (2012) Clinical features of Friedreich ataxia. J Child Neurol 27(9):1133–1137
Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P (2013) Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem 126(Suppl 1):103–117
Koeppen AH (2011) Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 303(1–2):1–12
Schulz JB, Pandolfo M (2013) 150 years of Friedreich ataxia: from its discovery to therapy. J Neurochem 126:1–3
Harding AE (1981) Early onset cerebellar ataxia with retained tendon reflexes: a clinical and genetic study of a disorder distinct from Friedreich’s ataxia. J Neurol Neurosurg Psychiatry 44(6):503–508
Pandolfo M (2009) Friedreich ataxia: the clinical picture. J Neurol 256(S1):3–8
Dürr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C et al (1996) Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 335(16):1169–1175
Schöls L, Amoiridis G, Przuntek H, Frank G, Epplen JT, Epplen C (1997) Friedreich’s ataxia. Revision of the phenotype according to molecular genetics. Brain 120(Pt 12):2131–2140
Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E et al (1999) Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 87(2):168–174
McCabe DJ, Ryan F, Moore DP, McQuaid S, King MD, Kelly A et al (2000) Typical Friedreich’s ataxia without GAA expansions and GAA expansion without typical Friedreich’s ataxia. J Neurol 247(5):346–355
Berciano J, Infante J, García A, Polo JM, Volpini V, Combarros O (2005) Very late-onset Friedreich’s ataxia with minimal GAA1 expansion mimicking multiple system atrophy of cerebellar type. Mov Disord 20(12):1643–1645
Galimanis A, Glutz L, Spiegel R, Burgunder J-M, Kaelin-Lang A (2008) Very-late-onset Friedreich ataxia with disturbing head tremor and without spinal atrophy—a case report. Mov Disord 23(7):1058–1059
Alvarez V, Arnold P, Kuntzer T (2013) Very late-onset Friedreich ataxia: later than life expectancy? J Neurol 260(5):1408–1409
Klockgether T, Zühlke C, Schulz JB, Bürk K, Fetter M, Dittmann H et al (1996) Friedreich’s ataxia with retained tendon reflexes: molecular genetics, clinical neurophysiology, and magnetic resonance imaging. Neurology 46(1):118–121
Coppola G, De Michele G, Cavalcanti F, Pianese L, Perretti A, Santoro L et al (1999) Why do some Friedreich’s ataxia patients retain tendon reflexes? A clinical, neurophysiological and molecular study. J Neurol 246(5):353–357
Pedroso JL, Braga-Neto P, Ricarte IF, Albuquerque MVC, Barsottini OGP (2013) Clinical spectrum of early onset cerebellar ataxia with retained tendon reflexes: an autosomal recessive ataxia not to be missed. Arq Neuropsiquiatr 71(6):345–348
Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB (2006) How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry 78(4):411–413
Bürk K, Schulz SR, Schulz JB (2013) Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem 126:118–124
Campuzano V, Montermini L, Moltó MD, Pianese L, Cossee M, Cavalcanti F et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254):1423–1427
Anheim M, Mariani L-L, Calvas P, Cheuret E, Zagnoli F, Odent S et al (2012) Exonic deletions of FXN and early-onset Friedreich ataxia. Arch Neurol 69(7):912–916
Cossee M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, Mandel JL et al (1997) Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A 94(14):7452–7457
Pandolfo M, Pastore A (2009) The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol 256(S1):9–17
Pianese L, Turano M, Casale Lo MS, De Biase I, Giacchetti M, Monticelli A et al (2004) Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry 75(7):1061–1063
Plasterer HL, Deutsch EC, Belmonte M, Egan E, Lynch DR, Rusche JR (2013) Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich’s ataxia. PLoS ONE 8(5):e63958
Koutnikova H, Campuzano V, Foury F, Dollé P, Cazzalini O, Koenig M (1997) Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet 16(4):345–351
Evans-Galea MV, Lockhart PJ, Galea CA, Hannan AJ, Delatycki MB (2014) Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia. Discov Med 17(91):25–35
Bidichandani SI, Ashizawa T, Patel PI (1998) The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 62(1):111–121
Ohshima K, Montermini L, Wells RD, Pandolfo M (1998) Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem 273(23):14588–14595
Grabczyk E, Usdin K (2000) The GAA*TTC triplet repeat expanded in Friedreich’s ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 28(14):2815–2822
Wells RD (2008) DNA triplexes and Friedreich ataxia. FASEB J 22(6):1625–1634
Grabczyk E, Mancuso M, Sammarco MC (2007) A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 35(16):5351–5359
Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R (2003) DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422(6934):909–913
Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat Chem Biol 2(10):551–558
Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, Sandi C et al (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17(5):735–746
Rai M, Soragni E, Jenssen K, Burnett R, Herman D, Coppola G et al (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 3(4):e1958
Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR et al (2010) Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich’s ataxia patients and in a mouse model. PLoS ONE 5(1):e8825
De Biase I, Rasmussen A, Monticelli A, Al-Mahdawi S, Pook M, Cocozza S et al (2007) Somatic instability of the expanded GAA triplet-repeat sequence in Friedreich ataxia progresses throughout life. Genomics 90(1):1–5
Perdomini M, Hick A, Puccio H, Pook MA (2013) Animal and cellular models of Friedreich ataxia. J Neurochem 126:65–79
Martelli A, Puccio H (2014) Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Front Pharmacol 5:130
Rouault TA, Tong WH (2008) Iron-sulfur cluster biogenesis and human disease. Trends Genet 24(8):398–407
De Castro M, García-Planells J, Monrós E, Cañizares J, Vázquez-Manrique R, Vílchez JJ et al (2000) Genotype and phenotype analysis of Friedreich’s ataxia compound heterozygous patients. Hum Genet 106(1):86–92
Xunclà M, Rodríguez-Revenga L, Madrigal I, Jiménez D, Milà M, Badenas C (2010) Protocol proposal for Friedreich ataxia molecular diagnosis using fluorescent and triplet repeat primed polymerase chain reaction. Transl Res 156(5):309–314
Muthuswamy S, Agarwal S, Dalal A (2013) Diagnosis and genetic counseling for Friedreich’s ataxia: a time for consideration of TP-PCR in an Indian setup. Hippokratia 17(1):38–41
Ciotti P, Di Maria E, Bellone E, Ajmar F, Mandich P (2004) Triplet repeat primed PCR (TP PCR) in molecular diagnostic testing for Friedreich ataxia. J Mol Diagn 6(4):285–289
Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR et al (2011) Mortality in Friedreich ataxia. J Neurol Sci 307(1–2):46–49
Mascalchi M (2013) The cerebellum looks normal in Friedreich ataxia. Am J Neuroradiol 34(2):E22
Mascalchi M, Salvi F, Piacentini S, Bartolozzi C (1994) Friedreich’s ataxia: MR findings involving the cervical portion of the spinal cord. AJR Am J Roentgenol 163(1):187–191
Chevis CF, da Silva CB, D’Abreu A, Lopes-Cendes I, Cendes F, Bergo FPG et al (2013) Spinal cord atrophy correlates with disability in Friedreich’s ataxia. Cerebellum 12(1):43–47
Della Nave R, Ginestroni A, Tessa C, Salvatore E, Bartolomei I, Salvi F et al (2008) Brain white matter tracts degeneration in Friedreich ataxia. An in vivo MRI study using tract-based spatial statistics and voxel-based morphometry. NeuroImage 40(1):19–25
Corben LA, Kashuk SR, Akhlaghi H, Jamadar S, Delatycki MB, Fielding J et al (2014) Myelin paucity of the superior cerebellar peduncle in individuals with Friedreich ataxia: an MRI magnetization transfer imaging study. J Neurol Sci 343(1–2):138–143
Bonilha da Silva C, Bergo FPG, D’Abreu A, Cendes F, Lopes-Cendes I, França MC (2014) Dentate nuclei T2 relaxometry is a reliable neuroimaging marker in Friedreich’s ataxia. Eur J Neurol 21(8):1131–1136
Solbach K, Kraff O, Minnerop M, Beck A, Schöls L, Gizewski ER et al (2014) Cerebellar pathology in Friedreich’s ataxia: atrophied dentate nuclei with normal iron content. NeuroImage Clin 6:93–99
Synofzik M, Godau J, Lindig T, Schöls L, Berg D (2011) Transcranial sonography reveals cerebellar, nigral, and forebrain abnormalities in Friedreich’s ataxia. Neurodegener Dis 8(6):470–475
Akhlaghi H, Corben L, Georgiou-Karistianis N, Bradshaw J, Delatycki MB, Storey E et al (2012) A functional MRI study of motor dysfunction in Friedreich’s ataxia. Brain Res 1471:138–154
Gilman S, Junck L, Markel DS, Koeppe RA, Kluin KJ (1990) Cerebral glucose hypermetabolism in Friedreich’s ataxia detected with positron emission tomography. Ann Neurol 28(6):750–757
Strawser CJ, Schadt KA, Lynch DR (2014) Therapeutic approaches for the treatment of Friedreich’s ataxia. Expert Rev Neurother 14(8):949–957
Parkinson MH, Schulz JB, Giunti P (2013) Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J Neurochem 126(Suppl 1):125–141
Lodi R, Hart PE, Rajagopalan B, Taylor DJ, Crilley JG, Bradley JL et al (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol 49(5):590–596
Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C et al (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62(4):621–626
Cooper JM, Korlipara LVP, Hart PE, Bradley JL, Schapira AHV (2008) Coenzyme Q 10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q 10 therapy. Eur J Neurol 15(12):1371–1379
Myers L, Farmer JM, Wilson RB, Friedman L, Tsou A, Perlman SL et al (2008) Antioxidant use in Friedreich ataxia. J Neurol Sci 267(1–2):174–176
Suno M, Nagaoka A (1984) Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619). Jpn J Pharmacol 35(2):196–198
Rustin P, Bonnet D, Rötig A, Munnich A, Sidi D (2004) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 62(3):524–525, author reply 525; discussion 525
Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S (2003) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60(10):1676–1679
Hausse AO, Aggoun Y, Bonnet D, Sidi D, Munnich A, Rötig A et al (2002) Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart 87(4):346–349
Buyse G, Mertens L, Di Salvo G, Matthijs I, Weidemann F, Eyskens B et al (2003) Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60(10):1679–1681
Lagedrost SJ, Sutton MSJ, Cohen MS, Satou GM, Kaufman BD, Perlman SL et al (2011) Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 161(3):639.e1–645.e1
Artuch R, Aracil A, Mas A, Colome C, Rissech M, Monrós E et al (2002) Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics 33(4):190–193
Pineda M, Arpa J, Montero R, Aracil A, Domínguez F, Galván M et al (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 12(6):470–475
Di Prospero NAN, Baker AA, Jeffries NN, Fischbeck KHK (2007) Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6(10):878–886
Lynch DRD, Perlman SLS, Meier TT (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 67(8):941–947
Arpa J, Sanz-Gallego I, Rodríguez-de-Rivera FJ, Domínguez-Melcón FJ, Prefasi D, Oliva-Navarro J et al (2013) Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich’s ataxia: an open-label trial. Cerebellum 12(5):713–720
Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH et al (2012) Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 105(1):91–102
Pandolfo M, Hausmann L (2013) Deferiprone for the treatment of Friedreich’s ataxia. J Neurochem 126:142–146
Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F et al (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110(1):401–408
Sturm B, Stupphann D, Kaun C, Boesch S, Schranzhofer M, Wojta J et al (2005) Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Investig 35(11):711–717
Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H et al (2008) Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord 23(13):1940–1944
Saccá F, Piro R, De Michele G, Acquaviva F, Antenora A, Carlomagno G et al (2011) Epoetin alfa increases frataxin production in Friedreich’s ataxia without affecting hematocrit. Mov Disord 26(4):739–742
Mariotti C, Fancellu R, Caldarazzo S, Nanetti L, Di Bella D, Plumari M et al (2012) Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord 27(3):446–449
Boesch S, Nachbauer W, Mariotti C, Saccá F, Filla A, Klockgether T et al (2014) Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord 29(7):935–939
Vyas PM, Tomamichel WJ, Pride PM, Babbey CM, Wang Q, Mercier J et al (2012) A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model. Hum Mol Genet 21(6):1230–1247
Tomassini B, Arcuri G, Fortuni S, Sandi C, Ezzatizadeh V, Casali C et al (2012) Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum Mol Genet 21(13):2855–2861
Seyer L, Greeley N, Foerster D, Strawser C, Gelbard S, Dong Y et al (2014) Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand. doi:10.1111/ane.12337
Chan PK, Torres R, Yandim C, Law PP, Khadayate S, Mauri M et al (2013) Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich’s ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet 22(13):2662–2675
Libri V, Yandim C, Athanasopoulos S, Loyse N, Natisvili T, Law PP et al (2014) Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet 384(9942):504–513
Perdomini M, Belbellaa B, Monassier L, Reutenauer L, Messaddeq N, Cartier N et al (2014) Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med 20(5):542–547
Acknowledgments
This work was supported by a grant from Fundação de Amparo à Pesquisa de São Paulo, FAPESP 2012/17494-3, São Paulo, Brazil.
Conflict of interest
The authors state that they have no disclosures and no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abrahão, A., Pedroso, J.L., Braga-Neto, P. et al. Milestones in Friedreich ataxia: more than a century and still learning. Neurogenetics 16, 151–160 (2015). https://doi.org/10.1007/s10048-015-0439-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10048-015-0439-z